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 2 
Abstract: 24 
The extracellular matrix (ECM) is a highly dynamic compartment that undergoes remodeling as a 25 
result of injury and repair. Over the past decade, mounting evidence in humans and rodents suggest 26 
that ECM remodeling is associated with diet-induced insulin resistance in several metabolic 27 
tissues. Additionally, integrin receptors for the ECM have also been implicated in the regulation 28 
of insulin action. This review will address what is currently known about the ECM, integrins and 29 
insulin action in the muscle, liver and adipose tissue. Understanding how ECM remodeling and 30 
integrin signaling regulates insulin action may aid in the development of new therapeutic targets 31 
for the treatment of insulin resistance and type 2 diabetes. 32 
 33 
  34 
 3 
Overview of the extracellular matrix and integrins 35 
The extracellular matrix (ECM) (Glossary) is composed of a diverse network of proteins and 36 
proteoglycans [1]. It provides a scaffold for cells and modulates biological processes including 37 
differentiation, cell migration, repair and development [2, 3]. The interaction between cells and 38 
the ECM is important for all organs. The ECM communicates with cells through transmembrane 39 
cell surface receptors called integrins [4]. Integrins bind the ECM and transduce signals through 40 
the plasma membrane to activate intracellular signaling. Integrins themselves lack kinase activity. 41 
Thus, they are reliant on scaffolding proteins and downstream kinases for signal transduction. 42 
Integrins signal through various proteins including focal adhesion kinase (FAK) and integrin-43 
linked kinase (ILK) (Box 1). The detailed structure and function of integrins have been reviewed 44 
elsewhere [1, 4, 5]. 45 
 46 
The ECM is a dynamic structure that remodels during times of injury and repair [6]. Pathological 47 
states are associated with ECM remodeling and alterations in integrin expression. In obese 48 
conditions, the expression of ECM proteins increases several-fold, while a shift appears to occur 49 
from low-density ECM proteins to more fibril-forming proteins. Several recent lines of evidence 50 
suggest that ECM remodeling and changes in integrin signaling in the diet-induced obese (DIO) 51 
state are associated with insulin resistance [7-16]. The potential mechanisms whereby this occurs 52 
are represented in Figure 1. Herein we discuss recent findings related to the emerging link between 53 
ECM remodeling, integrin signaling and insulin resistance in the skeletal muscle, liver, and 54 
adipose tissue. 55 
 56 
 57 
 4 
The Skeletal Muscle 58 
Mechanisms of High Fat Diet-induced ECM Remodeling in the Skeletal Muscle 59 
Inflammation and elevated transforming growth factor (TGF) β signaling are associated with 60 
muscle ECM remodeling, in obese mice and humans [17]. Mice fed a high fat diet (HFD) exhibit 61 
increased infiltration of pro-inflammatory M1-activated (CD11c+) macrophages in muscle [18]. 62 
Additionally, CD68+ macrophages are elevated in obese individuals [19]. The association between 63 
ECM remodeling and inflammation was further shown in a study by Kang et al. [9]. In this study, 64 
20 weeks of HF feeding in mice led to increased muscle collagen content associated with increased 65 
gene expression of the pro-inflammatory marker tumor necrosis factor (TNFα) and the 66 
macrophage marker F4/80. Importantly, gene expression for these inflammatory markers was 67 
diminished in mouse models of improved insulin sensitivity and decreased muscle collagen 68 
deposition. It is possible that increased recruitment of pro-inflammatory macrophages may lead to 69 
ECM remodeling via TGFβ-mediated Smad activation [20]. Smad3 activation is elevated in 70 
skeletal muscle biopsies of obese individuals compared to lean controls [17]. Collectively, this 71 
suggests that ECM remodeling in obese skeletal muscle occurs as a result of increased 72 
inflammation. 73 
 74 
The Skeletal Muscle ECM and Glucose Metabolism 75 
Insulin resistant muscle in obese and type 2 diabetic (T2D) humans is characterized by increased 76 
collagen deposition [7, 8]. Rapid weight gain in healthy young males resulted in impaired insulin 77 
sensitivity and the up-regulation of several muscle ECM genes [21]. There was no evidence of 78 
local adipose tissue or systemic inflammation despite weight gain, suggesting a key role for muscle 79 
ECM in the regulation of glucose homeostasis rather than secondary effects due to adipose tissue 80 
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inflammation.  81 
 82 
Muscle collagen content is also increased in DIO, insulin resistant mice [9]. Studies by Kang et al. 83 
showed that increased collagen deposition in the DIO state is due to in part to decreased muscle 84 
matrix metallopeptidase 9 (MMP9) activity [9], and that the genetic deletion of MMP9 in mice 85 
increases collagen deposition in the muscle and exacerbates muscle insulin resistance in HF-fed 86 
mice [15].  87 
 88 
Hyaluronan is an anionic, nonsulfated glycosaminoglycan. As a major component of the ECM, 89 
hyaluronan has multiple functions, including creating space between cells [22]. Serum hyaluronan 90 
is increased in T2D [23]. Insulin resistant animals have increased hyaluronan in muscles [16], aorta 91 
[24], and kidneys [25]. Elevated muscle hyaluronan levels are associated with muscle insulin 92 
resistance in the obese state. A reduction of muscle hyaluronan by intravenous injection of 93 
pegylated human recombinant hyaluronidase PH-20 (PEGPH20) results in a dose-dependent 94 
increase in glucose infusion rate and muscle glucose uptake during a hyperinsulinemic-euglycemic 95 
clamp [16]. This study showed for the first time that whole-body depletion of an ECM 96 
polysaccharide rescues insulin sensitivity in C57BL/6J HF-fed mice.  97 
 98 
There are several hypotheses as to how increased muscle ECM in the HF-fed state contributes to 99 
insulin resistance, which may co-exist. A first hypothesis, the ECM is a physical barrier to both 100 
glucose and insulin diffusion. Proteins buildup in the interstitial space and this impedes substrate 101 
delivery to the muscle by increasing diffusion distance. A second hypothesis is that increases in 102 
muscle ECM impair neo-vascular growth and vascular function. The ECM is in close contact with 103 
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the endothelium. Blood flow and capillary recruitment are critical for proper glucose and insulin 104 
delivery to the muscle. Vascular dysfunction and capillary rarefaction (reduced capillary density) 105 
have long been implicated in the development of muscle insulin resistance and T2D [26]. Reduced 106 
blood flow to the muscle is correlated with insulin resistance, and conversely, the number of 107 
muscle capillaries is positively related to peripheral insulin action [27, 28]. Additionally, three 108 
weeks of treatment with the hormone relaxin, improved muscle insulin action through effects on 109 
the vasculature [29]. Kang and colleagues have provided consistent evidence that increased muscle 110 
capillaries are associated with improved muscle insulin action in HF-fed mice [9, 15]. This was 111 
evident in several mouse models, including the muscle-specific mitochondrial targeted catalase 112 
transgenic mice [9], chronic sildenafil-treated mice [9] and hyaluronidase-treated mice [16]. In 113 
contrast, decreased muscle capillaries are associated with exacerbated muscle insulin resistance in 114 
the global MMP9 knockout mouse [15]. It is important to consider that the first and second 115 
hypotheses are inextricably linked, as a decrease in capillarity will increase spatial barriers and 116 
diffusion distance for hormones and nutrients. Collectively, these data strongly suggest endothelial 117 
dysfunction and muscle capillary rarefaction are potential mechanisms by which ECM remodeling 118 
mediates muscle insulin resistance.  Finally, the ECM may signal directly through muscle integrins 119 
to modulate insulin action (Figure 2).  This is discussed in detail below. 120 
 121 
Integrins and Skeletal Muscle Insulin Resistance 122 
Skeletal muscle expresses seven integrin α subunits (α1, α3, α4, α5, α6, α7, and αv), and are all 123 
associated with the β1 integrin subunit [30]. Remarkably, few studies have addressed the role of 124 
integrin signaling in the muscle with respect to muscle insulin resistance in vivo. The muscle-125 
specific deletion of integrin β1 in chow-fed mice results in decreased whole-body insulin 126 
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sensitivity, and decreased insulin-stimulated muscle glucose uptake during a hyperinsulinemic-127 
euglycemic clamp [31]. Notably, the loss of skeletal muscle β1 has no effect on liver or adipose 128 
tissue glucose metabolism. The decrease in insulin-stimulated muscle glucose uptake was 129 
associated with decreased muscle glycogen synthesis and decreased Akt S473 phosphorylation. 130 
Moreover, the whole-body deletion of integrin α2 in obese, HF-fed mice, partially reverses diet-131 
induced muscle insulin resistance, as evidenced by increased insulin-stimulated muscle glucose 132 
uptake during a hyperinsulinemic-euglycemic clamp, and increased insulin signaling [9] (Figure 133 
3). These data suggest that integrin signaling might be a mechanistic link between the muscle ECM 134 
and insulin resistance.  135 
 136 
The downstream integrin signaling molecule, FAK, has been implicated in the regulation of insulin 137 
action in the muscle [32-34]. FAK tyrosine phosphorylation is decreased in muscle from HF-fed 138 
rats [32]. The in vivo siRNA-mediated knockdown of FAK results in hyperglycemia, 139 
hyperinsulinemia, impaired glucose tolerance and decreased insulin action in chow-fed mice [34]. 140 
The overexpression of FAK in C2C12 mouse myoblasts increases insulin-stimulated glucose 141 
uptake [35]. Conversely, C2C12 cells transfected with siRNA against FAK exhibit decreased 142 
insulin-stimulated glucose uptake [32]. L6 myocytes transfected with antisense FAK display 143 
decreased insulin signaling associated with decreased insulin-stimulated glucose uptake, decreased 144 
glycogen synthesis and impaired Glut4 translocation [33]. Collectively, these studies suggest that 145 
integrins mediate muscle glucose metabolism via their effects on both vascularization and glucose 146 
transport through Glut4.  147 
 148 
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No information exists about the role of ILK in the regulation of muscle glucose homeostasis. Mice 149 
with a muscle-specific deletion of ILK have been generated and are viable [36]. Considering the 150 
interaction of ILK with several known insulin signaling molecules such as Akt and GSK-3β, it is 151 
highly possible that ILK modulates muscle insulin action. Future studies should be designed to 152 
determine whether ILK regulates muscle insulin action in the DIO mouse model. 153 
 154 
ECM remodeling and mechano-signal transduction  155 
ECM remodeling is also reflected by alterations in mechano-signal transduction to the nucleus and 156 
mitochondria [37, 38]. This may be a consequence of disturbances in actin and intermediate 157 
filament organization and/or the sarcoglycan complex, a junction whereby the myofiber interacts 158 
with the ECM. The sarcoglycan complex is critical for both force and mechano-signal transduction 159 
to the nucleus and mitochondrion. Disturbances in this complex produce metabolic effects [39]. 160 
Mice lacking the sarcoglycan complex in the muscle and adipose tissue demonstrate whole body 161 
insulin resistance attributed to impaired insulin-stimulated muscle glucose uptake [39]. 162 
Additionally, changes in the ECM of insulin resistant human muscle are accompanied by 163 
decreased abundance of the key filament organizational proteins, actinin 2 and desmin. It is 164 
plausible that these alterations may impair the ability of the muscle to adapt to exercise via 165 
compromised mechano-signal transduction to the nucleus or mitochondria that, under normal 166 
conditions, would induce gene transcription in response to exercise. In support of the ECM 167 
modulating mitochondrial function in the skeletal muscle, there is evidence that alterations in the 168 
collagen VI composition of the matrix affect mitochondrial function [37, 38]. Insulin resistant 169 
muscle is characterized by alterations in exercise tolerance and mitochondrial function, thus this 170 
provides another route whereby the ECM may regulate muscle insulin action. 171 
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The Liver 172 
Mechanisms of HFD-induced ECM Remodeling in the Liver  173 
The liver ECM expands with over-nutrition. Mice fed a HFD display increased hepatic staining 174 
for α-smooth muscle actin (SMA, a marker of stellate cell activation) and collagen, as well as 175 
increased collagen type I α1 gene expression [11]. Mice fed a HFD with high fructose water exhibit 176 
increased hepatic collagen type I α1 gene expression [10]. Moreover, Williams et al. recently 177 
demonstrated that mice fed a 60% HFD exhibit increased gene expression for collagen types I and 178 
III [12]. 179 
 180 
The specific process whereby ECM remodeling in the liver occurs in the presence of over-nutrition 181 
is undefined. However, one prevailing hypothesis is a “two hit” hypothesis [40]. The “first hit” is 182 
the accumulation of lipid metabolites. This leads to a series of events including lipotoxicity, 183 
oxidative stress, and inflammation that produce a “second hit”. The “second hit” promotes tissue 184 
injury and the activation of stellate cells. This process is initiated by autocrine and paracrine stimuli 185 
including inflammatory cytokines and growth factors such as TGFβ [41-43]. Increased TGFβ 186 
signaling is associated with hepatic collagen synthesis [44]. Once activated, stellate cells deposit 187 
ECM proteins in the space of Disse as part of a wound healing response, resulting in changes in 188 
the ECM and fibrosis [45]. Although it has been widely proposed that stellate cells are the main 189 
contributor to ECM deposition in the liver, it is possible that other cell types are involved [46]. 190 
The notion that stellate cells are the main contributor was based on in vitro studies performed in 191 
cell culture [47, 48]. However, several cell types in the intact liver are capable of ECM synthesis, 192 
including hepatocytes, endothelial cells, as well as stellate cells [2]. Considering that hepatocytes 193 
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comprise approximately 80% of the liver [49], it is feasible that they contribute to the hepatic 194 
ECM.      195 
 196 
The Liver ECM and Glucose Metabolism 197 
T2D in humans is associated with hepatic ECM remodeling [50, 51]. Patients with T2D exhibit 198 
increased staining for collagen type IV, α-SMA and a tendency for increased laminin staining [50]. 199 
In a separate study, liver biopsies from diabetic patients showed increased perisinusoidal fibrosis, 200 
characterized by immunostaining for laminin in sinusoidal spaces, as well as collagen type IV and 201 
α-SMA in the space of Disse [51]. It is important to note that early markers of ECM remodeling 202 
occur in diabetic patients prior to more advanced fibrosis and cirrhosis.  203 
 204 
It is evident that a diet high in fat is associated with insulin resistance and ECM remodeling in the 205 
liver. Bonner et al. [29] showed that three weeks of relaxin treatment in HF-fed mice, results in 206 
decreased hepatic collagen type III , and a subsequent improvement in hepatic insulin action. In 207 
light of this, it is important to note that only one study to date has demonstrated a causal link 208 
between ECM remodeling and insulin resistance [16]. Kang et al. showed that depletion of 209 
systemic hyaluronan via tail vein injection of a long-acting hyaluronidase reverses HFD-induced 210 
liver insulin resistance [16].  211 
 212 
CD44, the main hyaluronan cell surface receptor, is associated with T2D, as shown by expression-213 
based genome-wide association studies (GWAS) [52]. CD44 is ubiquitously expressed, and its 214 
expression level in liver is positively correlated with hepatic steatosis and insulin resistance, in 215 
obese humans and DIO mice [52, 53]. Kodama et al. reported that anti-CD44 antibody treatment 216 
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lowers glycemia, improves insulin sensitivity and hepatic steatosis in DIO mice [54]. It is 217 
important to note that CD44 can also interact with other ligands, such as osteopontin, collagens 218 
and MMPs. Therefore, it is unclear whether the phenotype of mice lacking functional CD44 is due 219 
to prevention of hyaluronan or osteopontin or both. Hence, the role of CD44 signaling in diet-220 
induced insulin resistance remains unclear, and warrants future investigation. Collectively, these 221 
studies highlight the role of the liver ECM in the regulation of glucose homeostasis. 222 
 223 
There are two existing hypotheses as to how the hepatic ECM contributes to changes in insulin 224 
action. The first is through cellular and microcirculatory changes as a result of diet-induced ECM 225 
remodeling. In the liver, it is reasonable to speculate that diet-induced ECM remodeling (i.e. 226 
sinusoidal capillarization) sensitizes the liver to further damage and may facilitate maladaptive 227 
changes in hepatic insulin action [55]. The liver is a major site of insulin clearance. It is estimated 228 
that 50% of insulin is extracted by the liver during the first pass, via a receptor-mediated process 229 
[56-58]. Hepatic insulin extraction from the circulation reflects the ability of the liver to adequately 230 
respond to an insulin stimulus. Patients with cirrhosis and chronic hepatitis display decreased 231 
hepatic insulin extraction, compared to normal subjects [59]. This decrease in insulin clearance 232 
can be attributed to either liver damage or shunting of the portal-systemic circulation [59]. An 233 
extension of this is impaired insulin action and ultimately insulin resistance. A second hypothesis 234 
is that, as in muscle, the ECM signals through integrins and this regulates insulin action.  235 
 236 
Integrins and Liver Insulin Resistance  237 
Six α integrin subunits (α1, α2, α3, α4, α5 and α6) are expressed in the liver, all of which are 238 
associated with the β1 integrin [60]. Of these six α subunits, only two integrins have been shown 239 
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to be expressed on the hepatocyte: integrin α1β1 and α5β1. Integrin α5β1 is a fibronectin receptor, 240 
and integrin α1β1 is a collagen binding integrin. The genetic whole body deletion of the integrin 241 
α1 subunit in mice exists and is viable [61]. Studies show that integrin α1β1 protects against the 242 
development of hepatic insulin resistance [9, 12] (Figure 4). Williams et al. demonstrated that 243 
integrin α1 protein expression is upregulated in hepatocytes isolated from HF-fed mice, compared 244 
to chow-fed controls [12]. Thus, to determine whether this response protected against hepatic 245 
metabolic impairments in DIO mice, insulin sensitivity was determined in integrin α1-null mice 246 
and their wild-type littermates. This study showed that deletion of the integrin α1 subunit results 247 
in severe hepatic insulin resistance in HF-fed mice and decreased hepatic insulin signaling. It is 248 
currently unknown whether some unidentified integrin α1 subunit binding protein is modulating 249 
the observed protective effect. Moreover, the role of integrin α5β1 in hepatic insulin action in vivo 250 
has not been investigated. It is possible, in the integrin α1 subunit null mice, that the severe hepatic 251 
insulin resistance is attributable to enhanced integrin α5β1 signaling. Future studies should be 252 
conducted to identify novel integrin α1 subunit binding partners and/or to determine whether 253 
integrin α5β1 contributes to or protects against diet-induced hepatic insulin resistance.  254 
 255 
FAK has been heavily implicated in the regulation of glucose homeostasis and insulin action in 256 
the liver [33, 34, 62]. FAK undergoes rapid tyrosine phosphorylation in livers from healthy rats 257 
upon insulin stimulation under euglycemic conditions in vivo [62]. This is consistent with a 258 
separate study showing that HepG2 cells transfected with mutant FAK constructs display 259 
decreased Akt Ser473 and GSK-3 Ser9 phosphorylation [63]. There was no difference in the 260 
insulin receptor phosphorylation or PI3K activity, upon insulin stimulation suggesting that FAK 261 
exerts its actions on insulin signaling downstream of the insulin receptor [64]. FAK tyrosine 262 
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phosphorylation is decreased in HF-fed mice [12]. The in vivo siRNA-mediated knockdown of 263 
FAK results in hyperglycemia, hyperinsulinemia, and impaired glucose tolerance in chow-fed 264 
mice [34]. Finally, fa/fa rats treated with a TNF-α neutralizing agent exhibited increased hepatic 265 
FAK phosphorylation associated with decreased hepatic glucose output during an insulin clamp 266 
[62, 65]. These studies suggest that decreased integrin signaling through FAK may facilitate the 267 
development of hepatic insulin resistance. 268 
 269 
Little is known about the role of integrin-linked kinase (ILK) in the regulation of hepatic insulin 270 
action. However, several studies suggest that ILK modulates the activation of several key insulin 271 
signaling proteins, including Akt and GSK-3β [66-68]. The stimulation of hepatic stellate cells in 272 
rats using carbon tetrachloride (CCl4) resulted in increased ILK protein expression, associated 273 
with enhanced phosphorylation of Akt, while the inhibition of ILK by siRNA prevented this [66]. 274 
In contrast, the phosphorylation of Akt Ser473 is not affected in mice with a hepatocyte-specific 275 
deletion of ILK [67], and ILK-deficient cells are capable of phosphorylating Akt at both Thr308 276 
and Ser473 upon insulin stimulation, similar to control cells [68]. Thus, the role of ILK in the 277 
regulation of Akt and GSK-3 phosphorylation is currently unresolved and more studies are 278 
necessary to address whether ILK mediates insulin signaling in vivo. The regulation of hepatic 279 
insulin action by integrins is multifaceted, and more studies are necessary to determine the actions 280 
of each integrin and integrin signaling molecule on hepatic insulin action, to aid in the 281 
determination of future therapeutics.  282 
 283 
 284 
 285 
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The Adipose Tissue 286 
 287 
Mechanisms of High Fat Diet-induced ECM Remodeling in Adipose Tissue 288 
The adipose tissue responds dynamically to nutrient excess through adipocyte hypertrophy and 289 
hyperplasia [69]. This is followed by increased production of pro-inflammatory adipokines, 290 
immune cell infiltration and ECM remodeling. Excessive collagen deposition has been observed 291 
in the adipose tissue of various models of overnutrition [13, 70, 71]. Collagen VI is a highly 292 
enriched ECM protein in adipose tissue and its expression is increased in obese humans [70]. 293 
Additionally, collagen gene expression (types I, III, V, and VI) is increased in adipose tissue from 294 
obese leptin receptor deficient db/db mice, and this is further exacerbated when the mice are fed a 295 
HFD [13]. Collectively, this suggests that ECM remodeling is a characteristic of obese adipose 296 
tissue. 297 
 298 
Hypoxia and inflammation are stimuli for ECM remodeling during adipose tissue expansion. HF 299 
feeding in rodents leads to the doubling of fat cell area accompanied by local hypoxia [72]. 300 
Hypoxia in obese adipose tissue occurs as the local vasculature fails to expand appropriately to 301 
meet the demands of increased fat mass. In support of this, gene expression of vascular endothelial 302 
growth factor (VEGF)-A and vessel density are decreased in the adipose tissue of ob/ob mice [72]. 303 
Hypoxia then leads to HIF1α activation and the secretion of pro-inflammatory cytokines from 304 
adipocytes [72, 73]. The combination of hypoxia and inflammation culminates in the pathological 305 
expansion of adipose ECM as adipocytes and recruited macrophages express and secrete collagens 306 
[70, 71, 74]. The mechanisms underlying ECM remodeling in adipose tissue have been reviewed 307 
in detail elsewhere [69, 75]. 308 
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The Adipose Tissue ECM and Glucose Metabolism 309 
One hallmark of metabolically dysfunctional adipose tissue is the pathological accumulation of 310 
ECM proteins. Increased collagen deposition is a physical barrier for adipocyte expansion during 311 
the development of obesity and this promotes the shunting of lipids into other tissues. A role for 312 
collagen in the obese, metabolically impaired adipose tissue was recently established [71]. The 313 
deletion of collagen VI in ob/ob mice results in un-impeded adipocyte expansion, improved 314 
glucose tolerance and insulin signaling. Additionally, the overexpression of the α3 chain of 315 
collagen VI (endotrophin) in mice stimulates deposition of other collagen types, mainly collagen 316 
I, III and VI and insulin resistance in the presence of a HFD [76]. 317 
 318 
Thrombospondin 1 (THBS1) is a large adhesive ECM glycoprotein expressed predominantly in 319 
visceral adipose tissue and its expression is elevated in insulin-resistant, obese humans [19].  In 320 
mice, HF feeding acutely induces adipose tissue Thbs1 expression and increases circulating 321 
THBS1 levels [14]. Genetic deletion of Thbs1 in mice protects against HFD induced adipose tissue 322 
inflammation and insulin resistance [14]. Circulating THBS1 may also induce fibrosis in skeletal 323 
muscle and induce insulin resistance [14]. This is evident as Thbs1-null skeletal muscle are 324 
protected from HFD-induced collagen deposition and insulin resistance. Moreover, expression of 325 
the pro-inflammatory ECM glycoprotein, tenacin C, is also upregulated in the adipose tissue of 326 
obese mice and humans [77] and may contribute to insulin resistance.  327 
 328 
The composition of ECM reflects a balance between matrix synthesis and degradation. Adipose 329 
tissue remodeling is altered in the obese state by ECM proteolysis via the fibrinolytic systems and 330 
matrix metalloproteinases (MMPs) [69]. MMPs are a family of zinc dependent proteinases 331 
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responsible for the degradation of ECM proteins [78]. MMP dysregulation has been implicated in 332 
the pathophysiology of obesity and diabetes. Plasma MMP2 and MMP9 concentrations are 333 
increased in obese [79] and diabetic [80, 81] individuals. Additionally, gene expression of adipose 334 
MMP9 correlates positively with altered HOMA-IR index in morbidly obese individuals [82].  335 
 336 
MMPs are regulated by tissue inhibitors of metalloproteinases (TIMPs), which comprise a family 337 
of four protease inhibitors: TIMP1, TIMP2, TIMP3 and TIMP4 [83]. Circulating TIMP-1 and 338 
TIMP-2 are increased in patients with metabolic syndrome and diabetes [81]. Overexpression of 339 
TIMP1 in pancreatic β-cells protects mice from streptozotocin-induced β-cell death and diabetes 340 
[84]. Likewise, genetic deletion of TIMP2 results in obesity and glucose intolerance in chow-fed 341 
mice that is further exacerbated in HF-fed mice [85]. TIMP3 is reduced in the adipose tissue of 342 
experimental models of obesity and insulin resistance [86]. Genetic deletion of TIMP3 in mice 343 
promotes adipose tissue inflammation [87] and TIMP3 overexpression in macrophages protects 344 
against adipose tissue inflammation and insulin resistance [88]. These data suggest that increased 345 
tissue TIMPs are protective from insulin resistance. This is paradoxical as TIMPs inhibit MMP 346 
activities. Thus in-depth investigations into the role of MMPs and TIMPs in obesity and insulin 347 
resistance should be a fruitful future direction for research. 348 
 349 
Concluding remarks and future perspectives 350 
The regulation of insulin action in the DIO state is complex. Many questions remain as to how 351 
metabolic disease develops and persists over time. The ECM and integrins are emerging as critical 352 
regulators of insulin action in the muscle, liver and adipose tissue. Until recently, few studies had 353 
addressed the contribution of the extracellular compartment to the regulation of glucose 354 
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metabolism. The observation that ECM remodeling occurs in both human and rodent models of 355 
insulin resistance and T2D was a great step forward in understanding this previously 356 
uncharacterized portion of insulin sensitive tissues. ECM remodeling in the obese state has been 357 
attributed to increased inflammation and the subsequent up regulation of pro-fibrotic signaling 358 
molecules including TGFβ. It is currently unknown how the ECM regulates insulin action; 359 
however several hypotheses exist to explain this phenomenon. First, ECM remodeling generates a 360 
mechanical barrier for (a) glucose and insulin transport in the muscle and liver and (b) adipocyte 361 
hypertrophy in the adipose tissue under conditions of overnutrition. Second, changes in the 362 
composition of the ECM results in downstream alterations in integrin signaling that culminate in 363 
impaired insulin action. In light of these hypotheses, several important outstanding questions 364 
endure (Box 2). Future studies that seek to determine the mechanisms underlying diet-induced 365 
ECM remodeling and the mechanistic link between ECM remodeling, integrin signaling and 366 
insulin action in metabolic tissues are vital to advancing this great new line of investigation. In 367 
conclusion, the ECM and integrins are important regulators of insulin action and represent novel 368 
therapeutic targets to treat the underlying insulin resistance associated with T2D.  369 
 370 
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Figure Legends 608 
Figure 1: A link between extracellular matrix remodeling and insulin resistance.  609 
A diet high in fat generates a state of chronic inflammation. This inflammatory response leads to 610 
increased ECM synthesis and decreased ECM degradation, resulting in increased deposition and 611 
remodeling of ECM. Increased levels of ECM lead to increased physical barriers for insulin and 612 
glucose transport, decreased vascular insulin delivery and decreased insulin signaling. The 613 
combination of all of these factors then culminates in insulin resistance.  614 
 615 
Figure 2: The role of integrin α2β1 diet-induced muscle insulin resistance.  616 
In the HF-fed state, capillary density and endothelial function are impaired. This results in 617 
decreased potential for glucose and insulin transport into the interstitial space despite 618 
hyperglycemia and hyperinsulinemia. Moreover, increased ECM deposition in the interstitial 619 
space also provides a physical barrier to glucose and insulin transport to the myocyte. Insulin 620 
signaling within the myocyte is impaired and this may be attributed to increased integrin α2β1 621 
signaling as a consequence of increased deposition of the ECM. This results in impaired Glut4 622 
translocation and decreased glucose transport into the myocyte. In contrast, the genetic deletion of 623 
the integrin α2 subunit results in improved insulin-stimulated muscle glucose uptake.  624 
 625 
Figure 3: The role of integrin α1β1 in diet-induced hepatic insulin resistance.  626 
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In the HF-fed state, sinusoidal capillarization occurs and this, in addition to increased ECM 627 
buildup in the space of Disse, results in decreased insulin transport to the hepatocyte despite 628 
hyperinsulinemia. Protein expression of the integrin α1 subunit is increased and this leads to 629 
increased α1β1 cell signaling. Upon insulin stimulation, the combination of both insulin and 630 
integrin α1β1 signaling results in some insulin signaling and the partial suppression of hepatic 631 
glucose output. In contrast, the genetic deletion of the integrin α1 subunit results in severe hepatic 632 
insulin resistance and no insulin-mediated suppression of hepatic glucose output. This is attributed 633 
to decreased insulin signaling. It is possible that this effect is mediated by integrin α5β1, the only 634 
other known integrin expressed on the hepatocyte, however this is currently unknown.  635 
 636 
Figure 4: Proposed model whereby integrins regulate insulin action.  637 
In the presence of insulin, integrin signaling through both integrin linked kinase (ILK) and focal 638 
adhesion kinase (FAK) promotes insulin action. Canonical insulin signaling occurs, however it is 639 
possible that other mechanisms exist whereby insulin exerts its actions within the cell. Several 640 
studies show that FAK is an important regulator of insulin action in both the muscle and liver. Less 641 
is known about ILK. However, Nck2 is an adaptor protein shared by both the insulin receptor and 642 
ILK. This suggests that there may be a physical link between the insulin receptor and integrins 643 
through Nck2 and ILK, allowing the centralization of signaling through this complex. Akt, a 644 
critical insulin signaling molecule, is a known binding partner of ILK. Additionally, integrin 645 
signaling has been shown to modulate the assembly of the cytoskeleton and this may have effects 646 
on both mitochondrial function and insulin action.  647 
 648 
 649 
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Text Box 1: Integrin signaling molecules   650 
Focal adhesion kinase  651 
Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase that localizes with integrin receptors 652 
at sites where cells attach to the ECM [89]. FAK undergoes rapid autophosphorylation at Tyr397 653 
upon integrin-mediated cell adhesion [90], and this is associated with increased catalytic activity. 654 
Additionally, FAK can be regulated by the growth factor receptors epidermal growth factor 655 
receptor (EGFR), fibroblast growth factor receptor (FGFR) and the insulin receptor [63, 91]. This 656 
results in the activation of several downstream signaling cascades including the MAPK and PI3K 657 
signaling pathways [63, 91]. In addition to its signaling properties, FAK is important for 658 
cytoskeletal stabilization and focal adhesion turnover [92]. 659 
Integrin-linked kinase and insulin action 660 
Integrin-linked kinase (ILK) is a highly conserved intracellular scaffolding protein. It interacts 661 
with the β1, β2 and β3-integrin cytoplasmic domains and numerous cytoskeleton-associated 662 
proteins. It is composed of three distinct domains: an N-terminus that contains five ankyrin repeats, 663 
a pleckstrin homology-like domain and a pseudokinase domain at the C-terminus. Considering 664 
that it is a scaffolding protein, it has been proposed that ILK modulates intracellular signaling 665 
through its ability to recruit a kinase or multiple kinases into a multiprotein complex. This complex 666 
then facilitates the activation of downstream signaling molecules upon insulin stimulation. The 667 
pseudokinase domain of ILK is an essential domain for the recruitment of adaptor proteins and/or 668 
signaling molecules including several proteins involved in insulin action such as PKB/Akt, PDK1 669 
and GSK-3β. Overexpression of ILK or insulin treatment results in increased GSK-3 and Akt 670 
phosphorylation [93]. Co-transfection of Akt with wild-type ILK in 293 cells resulted in an 671 
enhancement of phosphorylation of Akt Ser473 [93]. Several studies have shown that the ablation 672 
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of ILK results in decreased Akt Ser473 phosphorylation [94-96]. Moreover, ILK is connected to 673 
growth factor receptors through the adaptor protein Nck2 [97]. Therefore, although ILK lacks 674 
intrinsic kinase activity, it has been shown to regulate the activation of numerous intracellular 675 
growth factor signaling cascades [98-100]. 676 
 677 
Box 2: Outstanding questions 678 
 What role does inflammation have in diet-induced ECM remodeling? Which components 679 
of the inflammatory process are involved? Are the inflammatory stimuli acting locally or 680 
are they systemic? 681 
 When does ECM remodeling occur during a time-course of HF feeding in rodent models? 682 
How does this relate to insulin action? 683 
 Does ECM remodeling lead to insulin resistance by generating a physical barrier for 684 
glucose and insulin transport? 685 
 How do integrins regulate insulin action in vivo? What components of the integrin signaling 686 
cascade are important for insulin action? 687 
 688 
Glossary 689 
Collagen: the most abundant structural protein consisting of three α polypeptide chains folded into 690 
a triple helix formation. Collagen proteins are divided into subgroups depending on their 691 
organization and/or molecular size that include the fibril forming collagens type I and III, the 692 
basement membrane associated collagen type IV and collagen type V, a minor ECM component.  693 
Cirrhosis: late stage fibrosis of the liver as a result of different liver diseases and conditions such 694 
as hepatitis and chronic ethanol ingestion.  695 
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Endothelial dysfunction: deleterious alterations in endothelial physiology characterized by 696 
impaired endothelium-dependent vasodilation due to decreased availability of vasodilators such as 697 
NO and/or an increase in endothelium-derived contracting factors. 698 
Extracellular matrix (ECM): the space outside the cell composed of a complex meshwork of 699 
different proteins, proteoglycans, glycoproteins, polysaccharides and other structural proteins.  700 
Glycosaminoglycans: large linear polysaccharides containing repeating disaccharide units with 701 
an amino sugar (either GlcNAc or GalNAc) and an uronic acid. Five identified glycosaminoglycan 702 
chains exist: hyaluronan, dermatan, keratin, chondroitin and keratan.  703 
Homeostatic model assessment of insulin resistance (HOMA-IR): method to assess insulin 704 
resistance and β-cell function, from basal (fasting) glucose and insulin or C-peptide concentrations.  705 
Hyaluronan: an anionic, nonsulfated glycosaminoglycan. It is a major component of the ECM 706 
and has multiple functions, including creating space between cells and facilitating cell migration. 707 
Hyperinsulinemic-euglycemic clamp (insulin clamp): the gold standard for assessing insulin 708 
action in vivo. During the insulin clamp, insulin is infused at a constant rate and glucose is infused 709 
at a variable rate to maintain euglycemia. The amount of glucose that is infused reflects the insulin 710 
sensitivity. The insulin clamp can be combined with tracer techniques to determine sites of insulin 711 
resistance.  712 
Interstitial space: the narrow, fluid filled areas that surround the cells of a tissue. 713 
Myofibroblasts: cells in a state between a fibroblast and a smooth muscle cell. Fibrogenic cells 714 
are not part of the normal tissue and are only present following cellular injury. Often characterized 715 
by the presence of ruffled membranes and a highly active endoplasmic reticulum.  716 
Nonalcoholic fatty liver disease (NAFLD): also known as fatty liver disease, refers to the 717 
accumulation of excess lipids in liver cells that can induce inflammation and fibrosis.  718 
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Oxidative stress: the imbalance between the production of reactive oxygen species (ROS) and 719 
antioxidant defenses that may result in tissue damage. 720 
Relaxin: a protein hormone that acts through two G-protein coupled receptors RXFP1 and RXFP2 721 
and has effects on the cardiovascular system. The vascular effects of relaxin include vasodilation 722 
and a decrease in systemic vascular resistance. 723 
Space of Disse: The sinusoidal endothelium is separated from hepatocytes by the space of Disse 724 
where all metabolites from the bloodstream must pass through to reach the hepatocytes. The 725 
surface area of hepatocytes exposed to the space of Disse is greatly enhanced by the presence of 726 
microvilli. Under normal conditions, the space of Disse is filled with loosely assembled, low-727 
density extracellular matrix (ECM) proteins. 728 
Stellate cells: previously known as Ito cells, are quiescent vitamin A rich cells. Following liver 729 
injury, they transforms into activated proliferative and fibrogenic myofibroblasts. This process is 730 
initiated by autocrine and paracrine stimuli including inflammatory cytokines and growth factors. 731 
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